Search

Search Constraints

You searched for: Author/Creator Hanker, Lars

Search Results

1. 2022-RA-1505-ESGO Ovarian cancer retrospective European (O'CaRE) observational study: analysis of first-line (1L) outcomes in patients with ovarian cancer (OC) stratified by number of risk factors for progression. (20th October 2022)

2. 2022-RA-868-ESGO Risk for contralateral non sentinel metastases in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS vulva study. (20th October 2022)

4. Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study. Issue 7 (28th May 2020)

5. Association between obesity and vulvar cancer recurrence: an analysis of the AGO‐CaRE‐1 study. Issue 7 (July 2020)

6. Clonal Hematopoiesis–Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. (28th December 2021)

7. Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905–1914]. (September 2016)

8. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Issue 9 (12th April 2019)

9. Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5). Issue 2 (1st February 2014)

10. EP222/#606 Acid ceramidase (ASAH1) expression is associated with improved overall survival in patients with high-grade serous ovarian cancer from the ICON-7 trial. (4th December 2022)